These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8095649)

  • 21. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.
    Coukell AJ; Spencer CM
    Drugs; 1997 Mar; 53(3):520-38. PubMed ID: 9074848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
    Gill PS; Wernz J; Scadden DT; Cohen P; Mukwaya GM; von Roenn JH; Jacobs M; Kempin S; Silverberg I; Gonzales G; Rarick MU; Myers AM; Shepherd F; Sawka C; Pike MC; Ross ME
    J Clin Oncol; 1996 Aug; 14(8):2353-64. PubMed ID: 8708728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy.
    Gordon KB; Tajuddin A; Guitart J; Kuzel TM; Eramo LR; VonRoenn J
    Cancer; 1995 Apr; 75(8):2169-73. PubMed ID: 7697608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Doxorubicin liposome formulation gains marketing approval.
    Am J Health Syst Pharm; 1996 Jan; 53(2):116, 119. PubMed ID: 8653476
    [No Abstract]   [Full Text] [Related]  

  • 25. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.
    Amantea MA; Forrest A; Northfelt DW; Mamelok R
    Clin Pharmacol Ther; 1997 Mar; 61(3):301-11. PubMed ID: 9084455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy.
    Northfelt DW; Dezube BJ; Thommes JA; Levine R; Von Roenn JH; Dosik GM; Rios A; Krown SE; DuMond C; Mamelok RD
    J Clin Oncol; 1997 Feb; 15(2):653-9. PubMed ID: 9053490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DOXIL approved by FDA.
    AIDS Patient Care; 1995 Dec; 9(6):306. PubMed ID: 11361446
    [No Abstract]   [Full Text] [Related]  

  • 28. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.
    Northfelt DW; Dezube BJ; Thommes JA; Miller BJ; Fischl MA; Friedman-Kien A; Kaplan LD; Du Mond C; Mamelok RD; Henry DH
    J Clin Oncol; 1998 Jul; 16(7):2445-51. PubMed ID: 9667262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin.
    Gottlieb JJ; Washenik K; Chachoua A; Friedman-Kien A
    Lancet; 1997 Nov; 350(9088):1363-4. PubMed ID: 9365453
    [No Abstract]   [Full Text] [Related]  

  • 30. Kaposi's sarcoma after renal transplantation: treatment with liposomal doxorubicin.
    Boehringer M; Schwarz A; Keller F
    Nephrol Dial Transplant; 1999 May; 14(5):1342-3. PubMed ID: 10344407
    [No Abstract]   [Full Text] [Related]  

  • 31. Doxil receives FDA market clearance.
    AIDS Patient Care STDS; 1996 Apr; 10(2):135. PubMed ID: 11361702
    [No Abstract]   [Full Text] [Related]  

  • 32. Potentiation of cytotoxicity of Kaposi's sarcoma related to immunodeficiency syndrome (AIDS) by liposome-encapsulated doxorubicin.
    Masood R; Husain SR; Rahman A; Gill P
    AIDS Res Hum Retroviruses; 1993 Aug; 9(8):741-6. PubMed ID: 8217343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pulmonary Kaposi Sarcoma.
    Gottlieb M
    CJEM; 2016 Sep; 18(5):399-400. PubMed ID: 26791020
    [No Abstract]   [Full Text] [Related]  

  • 34. Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group.
    Goebel FD; Goldstein D; Goos M; Jablonowski H; Stewart JS
    Br J Cancer; 1996 Apr; 73(8):989-94. PubMed ID: 8611437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposomal-doxorubicin in human immunodeficiency virus-associated Kaposi's sarcoma.
    Poizot-Martin I; Giovannini M; Rosello R; Viallat JR; Sauniere JF; Dalmas AM; Genre D; Dhiver C; Gastaut JA
    J Clin Oncol; 1994 Mar; 12(3):645. PubMed ID: 8120565
    [No Abstract]   [Full Text] [Related]  

  • 36. Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma.
    Sharpe M; Easthope SE; Keating GM; Lamb HM
    Drugs; 2002; 62(14):2089-126. PubMed ID: 12269857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KS treatment inches forward.
    Vazquez E
    Posit Aware; 1996; 7(5):9. PubMed ID: 11363790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group.
    Stewart S; Jablonowski H; Goebel FD; Arasteh K; Spittle M; Rios A; Aboulafia D; Galleshaw J; Dezube BJ
    J Clin Oncol; 1998 Feb; 16(2):683-91. PubMed ID: 9469358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KS: a new drug and, maybe, a new bug.
    Gilden D
    GMHC Treat Issues; 1995 Jan; 9(1):11-12. PubMed ID: 11367378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of liposomal anthracyclines: from basics to clinical applications.
    Gabizon A; Goren D; Cohen R; Barenholz Y
    J Control Release; 1998 Apr; 53(1-3):275-9. PubMed ID: 9741935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.